Corcept Therapeutics to Announce Fourth Quarter and Full Year 2014 Revenue and Corporate Update and Host Conference Call
(firmenpresse) - MENLO PARK, CA -- (Marketwired) -- 01/22/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2014 revenue on January 29, 2015. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 38869004.
A replay will be available through February 12, 2015 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode is 3886 9004.
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive GR antagonist, is the company''s first FDA-approved medication. The company has a Phase 1 trial of mifepristone for the treatment of triple-negative breast cancer, a Phase 1 trial of CORT 125134, one of its proprietary, selective GR-II antagonists, and a portfolio of other selective GR antagonists that competitively block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.01.2015 - 15:05 Uhr
Sprache: Deutsch
News-ID 1332144
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MENLO PARK, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 224 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Corcept Therapeutics to Announce Fourth Quarter and Full Year 2014 Revenue and Corporate Update and Host Conference Call
"
steht unter der journalistisch-redaktionellen Verantwortung von
Corcept Therapeutics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
